Century Therapeutics Inc.

NASDAQ: IPSC · Real-Time Price · USD
0.56
0.01 (1.82%)
At close: Aug 15, 2025, 3:59 PM
0.58
3.17%
After-hours: Aug 15, 2025, 05:56 PM EDT

Century Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
109.16M 4.17M 791K 771K 855K 268K 148K 99K 1.72M 521K 2.22M 1.4M 1.06M n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a n/a 3.55M 1.79M 2.41M 2.17M 3.38M 2.77M 1.67M 21.2M 1.89M 1.04M 935K 948K
Gross Profit
109.16M 4.17M 791K 771K 855K -3.28M -1.64M -2.31M -450K -2.86M -550K -272K -20.14M -1.89M -1.04M -935K -948K
Operating Income
74.18M -37.28M -34.79M -34.76M -31.31M -43.76M -35.63M -35.08M -32.08M -33.31M -31.74M -31.35M -37.44M -27.97M -25.83M -23.02M -18.06M
Interest Income
2.42M 2.88M 3.31M 3.58M 3.24M 3.51M 3.49M 3.06M 2.62M 26K 1.03M 711K 253K n/a 140K 66K 28K
Pretax Income
76.56M -34.3M -31.23M -31.18M -28.06M -40.27M -32.13M -32.34M -30.06M -31.65M -30.72M -30.97M -37.5M -28.15M -26.01M -23.27M -18.35M
Net Income
76.56M -36.07M -31.23M -31.21M -28.06M -39.4M -32.72M -33.29M -31.26M -31.68M -30.75M -30.99M -37.51M -28.19M -26.01M -23.27M -18.35M
Selling & General & Admin
8.41M 7.75M 8.35M 8.31M 8.74M 8.59M 8.99M 8.23M 8.9M 8.24M 8.06M 8.25M 7.3M 6.18M 6.28M 4.09M 2.69M
Research & Development
26.58M 29.38M 27.23M 27.22M 23.42M 22.3M 22.79M 22.73M 24.9M 25.59M 25.9M 24.49M 31.2M 21.8M 19.55M 18.93M 15.37M
Other Expenses
n/a 4.33M n/a n/a n/a 13.14M 12K -186K -194K 2.07M 1.39M n/a 10M n/a n/a n/a 28K
Operating Expenses
34.99M 41.46M 35.58M 35.53M 32.16M 44.03M 31.77M 30.96M 33.8M 33.83M 33.96M 32.75M 38.49M 27.97M 25.83M 23.02M 18.06M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a 136K 404K 318K 296K 254K 238K 38K 245K 242K 314K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
34.99M 41.46M 35.58M 35.53M 32.16M 44.03M 31.77M 30.96M 33.8M 33.83M 33.96M 32.75M 38.49M 27.97M 25.83M 23.02M 18.06M
Income Tax Expense
n/a 1.78M -8K 22K 1K -869K 592K 950K 1.21M 32K 25K 18K 16K 43K 63K -10K n/a
Shares Outstanding (Basic)
86.02M 78.65M 84.7M 82.09M 62.3M 59.88M 59.45M 59.25M 58.61M 58.33M 57.97M 57.39M 57.05M 54.47M 54.47M 54.4M 54.82M
Shares Outstanding (Diluted)
86.1M 78.65M 84.7M 82.09M 62.3M 59.88M 59.45M 59.25M 58.61M 58.33M 57.97M 57.69M 57.05M 54.47M 54.47M 54.4M 54.82M
EPS (Basic)
0.89 -0.46 -0.37 -0.38 -0.45 -0.66 -0.55 -0.56 -0.53 -0.54 -0.53 -0.54 -0.66 -0.52 -0.48 -0.43 -0.33
EPS (Diluted)
0.89 -0.46 -0.37 -0.38 -0.45 -0.66 -0.55 -0.56 -0.53 -0.54 -0.53 -0.54 -0.66 -0.52 -0.48 -0.43 -0.33
EBITDA
77.4M -30.98M -27.94M -27.72M -28.08M -36.72M -30.34M -29.8M -27.48M -27.85M -27.58M -28.97M -37.18M -26.92M -24.64M -22.09M -17.32M
EBIT
74.18M -34.3M -31.23M -31.18M -31.31M -40.27M -32.13M -32.2M -29.71M -31.33M -30.43M -30.72M -37.26M -27.91M -25.76M -23.03M -18.11M
Depreciation & Amortization
3.22M 3.32M 3.3M 3.46M 3.23M 3.55M 1.79M 2.41M 2.17M 3.38M 2.77M 1.67M 1.16M 1.89M 1.04M 935K 948K